Oral Antidiabetic Agents View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-02

AUTHORS

Andrew J. Krentz, Clifford J. Bailey

ABSTRACT

Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals. More... »

PAGES

385-411

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005

DOI

http://dx.doi.org/10.2165/00003495-200565030-00005

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020874837

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15669880


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biguanides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoside Hydrolase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazolidinediones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Southampton NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.430506.4", 
          "name": [
            "Southampton University Hospitals NHS Trust, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krentz", 
        "givenName": "Andrew J.", 
        "id": "sg:person.0676605226.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676605226.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aston University", 
          "id": "https://www.grid.ac/institutes/grid.7273.1", 
          "name": [
            "Life and Health Sciences, Aston Pharmacy School, Aston University, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Clifford J.", 
        "id": "sg:person.01012617522.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012617522.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.281.21.2005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000047333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/14746514030030051001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000069406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/14746514030030051001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000069406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2003.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000975444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa012512", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001036745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.1999.00166.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001335743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.327.7421.951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002098315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.325.7369.860", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002420008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200060050-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003434116", 
          "https://doi.org/10.2165/00003495-200060050-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200060050-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003434116", 
          "https://doi.org/10.2165/00003495-200060050-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7861/clinmedicine.1-6-472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003704904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200464120-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005716893", 
          "https://doi.org/10.2165/00003495-200464120-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200464120-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005716893", 
          "https://doi.org/10.2165/00003495-200464120-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000103683.99399.7e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007027759"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1153-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007171833", 
          "https://doi.org/10.1007/s00125-003-1153-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1153-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007171833", 
          "https://doi.org/10.1007/s00125-003-1153-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200017050-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008294814", 
          "https://doi.org/10.2165/00002512-200017050-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200017050-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008294814", 
          "https://doi.org/10.2165/00002512-200017050-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.51.9.2796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011011786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200262100-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012559787", 
          "https://doi.org/10.2165/00003495-200262100-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200262100-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012559787", 
          "https://doi.org/10.2165/00003495-200262100-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.r100034200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014264954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06715-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014936450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07037-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015697368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021778", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018344641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1463-1326.2000.00053.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018580225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07019-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018881858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1463-1326.2002.00189.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019630371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra041001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019925590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.287.19.2570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023285132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0531-5131(02)01278-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023539162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0531-5131(02)01278-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023539162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2362.2004.01381.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025780657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199411040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026564315", 
          "https://doi.org/10.2165/00002018-199411040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)90002-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031243451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199602293340906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031600279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/bst0300333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031790720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/bst0300333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031790720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.2002.00734.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033160698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.24.4.758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035419921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/3-540-29832-0_122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037474338", 
          "https://doi.org/10.1007/3-540-29832-0_122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-002-0932-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037610401", 
          "https://doi.org/10.1007/s00125-002-0932-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-002-0932-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037610401", 
          "https://doi.org/10.1007/s00125-002-0932-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08905-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040832542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.290.4.486", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042599369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2125.1999.00030.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043231388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00916-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043406867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00916-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043406867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci13505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043705336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci13505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043705336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200118050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044292364", 
          "https://doi.org/10.2165/00002512-200118050-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200118050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044292364", 
          "https://doi.org/10.2165/00002512-200118050-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m106424200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045195003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci10762", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045265009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.287.3.360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045284159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046239186", 
          "https://doi.org/10.1007/s001250051247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046239186", 
          "https://doi.org/10.1007/s001250051247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.25.12.2244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047089706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.321.7256.252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048879453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1515/jpem.2002.15.s2.737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049225232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.1999.00023.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049451052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1228-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050026340", 
          "https://doi.org/10.1007/s00125-003-1228-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1228-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050026340", 
          "https://doi.org/10.1007/s00125-003-1228-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200363100-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050165822", 
          "https://doi.org/10.2165/00003495-200363100-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200363100-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050165822", 
          "https://doi.org/10.2165/00003495-200363100-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2003.10.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051876972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.321.7258.394", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052043497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.21.9.976", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070732325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.37.12.1595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070735404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.37.12.1595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070741229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.15.6.737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070745704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.16.1.184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070745798"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.20.6.925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070747742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.22.6.960", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-131-4-199908170-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073703508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-134-1-200101020-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073704512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-137-1-200207020-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073705509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpendo.1999.277.1.e1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074492025"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-02", 
    "datePublishedReg": "2005-02-01", 
    "description": "Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003495-200565030-00005", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "65"
      }
    ], 
    "name": "Oral Antidiabetic Agents", 
    "pagination": "385-411", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6375df6f71f55c06beb95c3ae0fb82945e4be609268fe9352eba8dbfd4e50c45"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15669880"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-200565030-00005"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020874837"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-200565030-00005", 
      "https://app.dimensions.ai/details/publication/pub.1020874837"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70066_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003495-200565030-00005"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'


 

This table displays all metadata directly associated to this object as RDF triples.

315 TRIPLES      21 PREDICATES      101 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-200565030-00005 schema:about N2314c95f57174fc49136351b4c9eba75
2 N52fd73bc658a4b4cb9aae843a9a6e452
3 N56fb4ee0f13c4b8eaba9214cac8a4a40
4 N5ebb58ed5c4241b09f1a0cae00d2d1bd
5 N607b25ef41a04a2f9498e6a086a3bad5
6 N69a7aacde2914548b59d1f071d60fe75
7 N74c8f4d576c74f96ad188cc39723274f
8 Nb453639c8eb242529e94ef59d59f7753
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author Nb882d5db49a34765875aa7e59c529624
12 schema:citation sg:pub.10.1007/3-540-29832-0_122
13 sg:pub.10.1007/s00125-002-0932-4
14 sg:pub.10.1007/s00125-003-1153-1
15 sg:pub.10.1007/s00125-003-1228-z
16 sg:pub.10.1007/s001250051247
17 sg:pub.10.2165/00002018-199411040-00002
18 sg:pub.10.2165/00002512-200017050-00007
19 sg:pub.10.2165/00002512-200118050-00003
20 sg:pub.10.2165/00003495-200060050-00004
21 sg:pub.10.2165/00003495-200262100-00004
22 sg:pub.10.2165/00003495-200363100-00002
23 sg:pub.10.2165/00003495-200464120-00006
24 https://doi.org/10.1001/jama.281.21.2005
25 https://doi.org/10.1001/jama.287.19.2570
26 https://doi.org/10.1001/jama.287.3.360
27 https://doi.org/10.1001/jama.290.4.486
28 https://doi.org/10.1016/j.amjmed.2003.08.010
29 https://doi.org/10.1016/j.amjmed.2003.10.017
30 https://doi.org/10.1016/s0140-6736(00)90002-3
31 https://doi.org/10.1016/s0140-6736(01)06715-0
32 https://doi.org/10.1016/s0140-6736(02)08905-5
33 https://doi.org/10.1016/s0140-6736(98)07019-6
34 https://doi.org/10.1016/s0140-6736(98)07037-8
35 https://doi.org/10.1016/s0531-5131(02)01278-5
36 https://doi.org/10.1016/s0735-1097(03)00916-1
37 https://doi.org/10.1042/bst0300333
38 https://doi.org/10.1046/j.1365-2125.1999.00030.x
39 https://doi.org/10.1046/j.1463-1326.2000.00053.x
40 https://doi.org/10.1046/j.1463-1326.2002.00189.x
41 https://doi.org/10.1046/j.1464-5491.1999.00023.x
42 https://doi.org/10.1046/j.1464-5491.1999.00166.x
43 https://doi.org/10.1046/j.1464-5491.2002.00734.x
44 https://doi.org/10.1056/nejm199602293340906
45 https://doi.org/10.1056/nejmoa012512
46 https://doi.org/10.1056/nejmoa021778
47 https://doi.org/10.1056/nejmra041001
48 https://doi.org/10.1074/jbc.m106424200
49 https://doi.org/10.1074/jbc.r100034200
50 https://doi.org/10.1097/00041433-200312000-00004
51 https://doi.org/10.1111/j.1365-2362.2004.01381.x
52 https://doi.org/10.1136/bmj.321.7256.252
53 https://doi.org/10.1136/bmj.321.7258.394
54 https://doi.org/10.1136/bmj.325.7369.860
55 https://doi.org/10.1136/bmj.327.7421.951
56 https://doi.org/10.1152/ajpendo.1999.277.1.e1
57 https://doi.org/10.1161/01.cir.0000103683.99399.7e
58 https://doi.org/10.1172/jci10762
59 https://doi.org/10.1172/jci13505
60 https://doi.org/10.1177/14746514030030051001
61 https://doi.org/10.1515/jpem.2002.15.s2.737
62 https://doi.org/10.2337/diab.21.9.976
63 https://doi.org/10.2337/diab.37.12.1595
64 https://doi.org/10.2337/diabetes.37.12.1595
65 https://doi.org/10.2337/diabetes.51.9.2796
66 https://doi.org/10.2337/diacare.15.6.737
67 https://doi.org/10.2337/diacare.16.1.184
68 https://doi.org/10.2337/diacare.20.6.925
69 https://doi.org/10.2337/diacare.22.6.960
70 https://doi.org/10.2337/diacare.24.4.758
71 https://doi.org/10.2337/diacare.25.12.2244
72 https://doi.org/10.7326/0003-4819-131-4-199908170-00008
73 https://doi.org/10.7326/0003-4819-134-1-200101020-00014
74 https://doi.org/10.7326/0003-4819-137-1-200207020-00009
75 https://doi.org/10.7861/clinmedicine.1-6-472
76 schema:datePublished 2005-02
77 schema:datePublishedReg 2005-02-01
78 schema:description Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.
79 schema:genre research_article
80 schema:inLanguage en
81 schema:isAccessibleForFree false
82 schema:isPartOf N61c32fb7bbb14b9bb216deac27859379
83 Nc561f54b9a974dbe8592ad32147fcdfa
84 sg:journal.1084788
85 schema:name Oral Antidiabetic Agents
86 schema:pagination 385-411
87 schema:productId N39b1281662b54130a47d8ebaa3933b5e
88 N90dc53f8eb7440a999ce2aca71e563c4
89 Nde8b170286b440b9938947f7c765dd7f
90 Ne9f516dfd4794cf695cfe5f7397ae913
91 Nfa915e48fdfc4f858efda5130cff6b96
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020874837
93 https://doi.org/10.2165/00003495-200565030-00005
94 schema:sdDatePublished 2019-04-11T12:43
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N99902230c87a45bc99cc9a93f93e2cbc
97 schema:url http://link.springer.com/10.2165/00003495-200565030-00005
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0c4321a6c58f4a59bbecfcce4a1cabd9 rdf:first sg:person.01012617522.23
102 rdf:rest rdf:nil
103 N2314c95f57174fc49136351b4c9eba75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Hypoglycemic Agents
105 rdf:type schema:DefinedTerm
106 N39b1281662b54130a47d8ebaa3933b5e schema:name readcube_id
107 schema:value 6375df6f71f55c06beb95c3ae0fb82945e4be609268fe9352eba8dbfd4e50c45
108 rdf:type schema:PropertyValue
109 N52fd73bc658a4b4cb9aae843a9a6e452 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Glycoside Hydrolase Inhibitors
111 rdf:type schema:DefinedTerm
112 N56fb4ee0f13c4b8eaba9214cac8a4a40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Biguanides
114 rdf:type schema:DefinedTerm
115 N5ebb58ed5c4241b09f1a0cae00d2d1bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Thiazolidinediones
117 rdf:type schema:DefinedTerm
118 N607b25ef41a04a2f9498e6a086a3bad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Sulfonylurea Compounds
120 rdf:type schema:DefinedTerm
121 N61c32fb7bbb14b9bb216deac27859379 schema:volumeNumber 65
122 rdf:type schema:PublicationVolume
123 N69a7aacde2914548b59d1f071d60fe75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Diabetes Mellitus, Type 2
125 rdf:type schema:DefinedTerm
126 N74c8f4d576c74f96ad188cc39723274f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Randomized Controlled Trials as Topic
128 rdf:type schema:DefinedTerm
129 N90dc53f8eb7440a999ce2aca71e563c4 schema:name dimensions_id
130 schema:value pub.1020874837
131 rdf:type schema:PropertyValue
132 N99902230c87a45bc99cc9a93f93e2cbc schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 Nb453639c8eb242529e94ef59d59f7753 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 Nb882d5db49a34765875aa7e59c529624 rdf:first sg:person.0676605226.07
138 rdf:rest N0c4321a6c58f4a59bbecfcce4a1cabd9
139 Nc561f54b9a974dbe8592ad32147fcdfa schema:issueNumber 3
140 rdf:type schema:PublicationIssue
141 Nde8b170286b440b9938947f7c765dd7f schema:name doi
142 schema:value 10.2165/00003495-200565030-00005
143 rdf:type schema:PropertyValue
144 Ne9f516dfd4794cf695cfe5f7397ae913 schema:name nlm_unique_id
145 schema:value 7600076
146 rdf:type schema:PropertyValue
147 Nfa915e48fdfc4f858efda5130cff6b96 schema:name pubmed_id
148 schema:value 15669880
149 rdf:type schema:PropertyValue
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1084788 schema:issn 0012-6667
157 1179-1950
158 schema:name Drugs
159 rdf:type schema:Periodical
160 sg:person.01012617522.23 schema:affiliation https://www.grid.ac/institutes/grid.7273.1
161 schema:familyName Bailey
162 schema:givenName Clifford J.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012617522.23
164 rdf:type schema:Person
165 sg:person.0676605226.07 schema:affiliation https://www.grid.ac/institutes/grid.430506.4
166 schema:familyName Krentz
167 schema:givenName Andrew J.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676605226.07
169 rdf:type schema:Person
170 sg:pub.10.1007/3-540-29832-0_122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037474338
171 https://doi.org/10.1007/3-540-29832-0_122
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s00125-002-0932-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037610401
174 https://doi.org/10.1007/s00125-002-0932-4
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00125-003-1153-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007171833
177 https://doi.org/10.1007/s00125-003-1153-1
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s00125-003-1228-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1050026340
180 https://doi.org/10.1007/s00125-003-1228-z
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s001250051247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046239186
183 https://doi.org/10.1007/s001250051247
184 rdf:type schema:CreativeWork
185 sg:pub.10.2165/00002018-199411040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026564315
186 https://doi.org/10.2165/00002018-199411040-00002
187 rdf:type schema:CreativeWork
188 sg:pub.10.2165/00002512-200017050-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008294814
189 https://doi.org/10.2165/00002512-200017050-00007
190 rdf:type schema:CreativeWork
191 sg:pub.10.2165/00002512-200118050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044292364
192 https://doi.org/10.2165/00002512-200118050-00003
193 rdf:type schema:CreativeWork
194 sg:pub.10.2165/00003495-200060050-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003434116
195 https://doi.org/10.2165/00003495-200060050-00004
196 rdf:type schema:CreativeWork
197 sg:pub.10.2165/00003495-200262100-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012559787
198 https://doi.org/10.2165/00003495-200262100-00004
199 rdf:type schema:CreativeWork
200 sg:pub.10.2165/00003495-200363100-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050165822
201 https://doi.org/10.2165/00003495-200363100-00002
202 rdf:type schema:CreativeWork
203 sg:pub.10.2165/00003495-200464120-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005716893
204 https://doi.org/10.2165/00003495-200464120-00006
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1001/jama.281.21.2005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000047333
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1001/jama.287.19.2570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023285132
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1001/jama.287.3.360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045284159
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1001/jama.290.4.486 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042599369
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/j.amjmed.2003.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000975444
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/j.amjmed.2003.10.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051876972
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s0140-6736(00)90002-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031243451
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s0140-6736(01)06715-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014936450
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s0140-6736(02)08905-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040832542
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s0140-6736(98)07019-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018881858
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s0140-6736(98)07037-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015697368
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/s0531-5131(02)01278-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023539162
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1016/s0735-1097(03)00916-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043406867
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1042/bst0300333 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031790720
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1046/j.1365-2125.1999.00030.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043231388
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1046/j.1463-1326.2000.00053.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1018580225
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1046/j.1463-1326.2002.00189.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019630371
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1046/j.1464-5491.1999.00023.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049451052
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1046/j.1464-5491.1999.00166.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001335743
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1046/j.1464-5491.2002.00734.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033160698
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1056/nejm199602293340906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031600279
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1056/nejmoa012512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001036745
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1056/nejmoa021778 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018344641
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmra041001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019925590
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1074/jbc.m106424200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045195003
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1074/jbc.r100034200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014264954
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00041433-200312000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003768084
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1111/j.1365-2362.2004.01381.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025780657
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1136/bmj.321.7256.252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048879453
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1136/bmj.321.7258.394 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052043497
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1136/bmj.325.7369.860 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002420008
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1136/bmj.327.7421.951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002098315
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1152/ajpendo.1999.277.1.e1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074492025
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1161/01.cir.0000103683.99399.7e schema:sameAs https://app.dimensions.ai/details/publication/pub.1007027759
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1172/jci10762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045265009
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1172/jci13505 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043705336
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1177/14746514030030051001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000069406
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1515/jpem.2002.15.s2.737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049225232
281 rdf:type schema:CreativeWork
282 https://doi.org/10.2337/diab.21.9.976 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070732325
283 rdf:type schema:CreativeWork
284 https://doi.org/10.2337/diab.37.12.1595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070735404
285 rdf:type schema:CreativeWork
286 https://doi.org/10.2337/diabetes.37.12.1595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070741229
287 rdf:type schema:CreativeWork
288 https://doi.org/10.2337/diabetes.51.9.2796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011011786
289 rdf:type schema:CreativeWork
290 https://doi.org/10.2337/diacare.15.6.737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070745704
291 rdf:type schema:CreativeWork
292 https://doi.org/10.2337/diacare.16.1.184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070745798
293 rdf:type schema:CreativeWork
294 https://doi.org/10.2337/diacare.20.6.925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070747742
295 rdf:type schema:CreativeWork
296 https://doi.org/10.2337/diacare.22.6.960 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748809
297 rdf:type schema:CreativeWork
298 https://doi.org/10.2337/diacare.24.4.758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035419921
299 rdf:type schema:CreativeWork
300 https://doi.org/10.2337/diacare.25.12.2244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047089706
301 rdf:type schema:CreativeWork
302 https://doi.org/10.7326/0003-4819-131-4-199908170-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073703508
303 rdf:type schema:CreativeWork
304 https://doi.org/10.7326/0003-4819-134-1-200101020-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073704512
305 rdf:type schema:CreativeWork
306 https://doi.org/10.7326/0003-4819-137-1-200207020-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073705509
307 rdf:type schema:CreativeWork
308 https://doi.org/10.7861/clinmedicine.1-6-472 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003704904
309 rdf:type schema:CreativeWork
310 https://www.grid.ac/institutes/grid.430506.4 schema:alternateName University Hospital Southampton NHS Foundation Trust
311 schema:name Southampton University Hospitals NHS Trust, Southampton, UK
312 rdf:type schema:Organization
313 https://www.grid.ac/institutes/grid.7273.1 schema:alternateName Aston University
314 schema:name Life and Health Sciences, Aston Pharmacy School, Aston University, Birmingham, UK
315 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...